Anti-Delta Opioid Receptor antibody
Specifications
| Product Cat#: | AB-06-1354 |
| Product type: | Primary antibody |
| Antigen: | Delta Opioid Receptor |
| Immunogen: | Recombinant protein |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:500); Flow Cytometry (1:50-1:200) |
| Reactivity: | Human, Mouse, Rat |
| Clonality (clone number): | Monoclonal (SN20-04) |
| Form: | Liquid |
| Buffer: | 1*TBS (pH 7.4), 1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide. |
| Concentration: | 1 mg/ml |
| Purity: | Protein A affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | D-OR-1 antibody |
| Delta type opioid receptor antibody | |
| Delta type opioid receptor DOR 1 antibody | |
| Delta type opioid receptor DOR1 antibody | |
| Delta-type opioid receptor antibody | |
| DOR 1 antibody | |
| DOR-1 antibody | |
| DOR1 antibody | |
| mDOR antibody | |
| Nbor antibody | |
| Opioid receptor delta 1 antibody | |
| OPRD 1 antibody | |
| OPRD antibody | |
| OPRD_HUMAN antibody | |
| Oprd1 antibody |
Show More
Target information
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine.
Provider
Erpantech Laboratory
